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1. Introduction
  The leishmaniases are a wide spectrum of vector born 
disease with great epidemiological and clinical diversity. It 
is caused by more than 20 species of protozoan parasite that 
belongs to family kinetoplastida and genus Leishmania. The 
disease is spread by more than 30 species of Phlebotamine 
sand fly in old world and Leutzomia in new world[1]. The 
digenetic life cycle of Leishmania consists of motile, 
flagellated, extracellular promastigotes form in the gut of 
sand fly vector that infects mammalian host and transform 
into nonmotile, nonflagellated amastigotes form, which 
survive and multiply within phagolysosomal compartment 
of macrophages. Leishmaniasis has traditionally been 
classified into three major clinical forms: visceral (VL), 
cutaneous (CL), and mucocutaneous leishmaniasis (MCL), 
which differ in immunopathologies and degree of morbidity 
and mortality. Most VL caused by Leishmania donovani 
is fatal if untreated, whereas CL caused by Leishmania 
major, Leishmania mexicana, Leishmania braziliensis, and 
Leishmania panamensis, frequently self cures within 3-18 
months, leaving disfiguring scars[2].
  Over more than 90% cases of VL ensue in five countries: 
India, Bangladesh, Nepal, Sudan and Brazil and 90% of 
CL cases occur in seven countries: Afghanistan, Algeria, 
Brazil, Iran, Peru, Saudi Arabia and Syria[3]. However, these 
numbers only reflects the reported cases and there is gross 
under reporting of cases in endemic areas that hide the 
actual severity of the disease[4]. Although, spread of disease 
in endemic and non-endemic regions is multi-factorial 
but lack of effective control measures for both, parasite and 
its vector are main factors. The poor knowledge about the 
disease and lack of effective health policies are the primary 
hurdles in the elimination of leishmaniasis from every 
The control of Leishmania infection relies primarily on chemotherapy till date. Resistance 
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corner of the world is far from reality. 
  Soon after realization that Leishmania causes this disease, 
generic pentavalent antimonials have been the cornerstone 
of leishmanial chemotherapy in disease endemic countries 
especially in Indian subcontinent[5]. In addition, branded 
sodium stibogluconate and meglumine antimoniate are 
the alternatives of generic antimonials. The other second 
line drugs like amphotericin B, its liposomal formulations 
and miltefosine are being used in the treatment with more 
efficacies and dramatic potential for curing leishmaniasis 
however, they are comparably costlier than the generic 
antimony[6]. Other drugs like paromomycin and pentamidine 
have shown some usefulness and could be a potential 
supplement in the drugs regimen but their use and 
availability in disease endemic regions is limited[6-8]. 
  Identification and characterization of cellular targets and 
answering the problem of drug resistance in leishmaniasis 
has always been the main thrust of protozoan research 
worldwide. The recent advancements in innovative animal 
models and parasites with reporter gene constructs have 
provided rapid and high through output drug screening 
methods in both, in vivo and in vitro[9,10]. Unfortunately 
no vaccine candidates either prophylactic or preventive 
are under animal or clinical trials[11-13]. Thus it becomes 
significantly important to search an effective drug/s and/or 
a prophylactic vaccine/s for an early and effective control 
of leishmaniasis. This review gives an overview of 1) drugs 
that are being used and/or are still in phase of clinical trials, 
2) mechanisms of drug action and resistance, 3) and finally 
elaborates biochemical machineries and enzymes as new 
potential drug targets.  
  
2. Current scenario of available drugs
2.1. Pentavalent antimonials
  Pentavalent antimonials, the generic sodium stibogluconate 
(pentosam) and branded meglumine antimoniate etc, are 
being used in the treatment of leishmaniasis over more 
than five decades and still they are the first line drugs of 
choice where resistance is not reported[14]. The growing 
incidence of resistance has raised serious concern for its use 
in disease endemic area[15]. The pentavalent antimoniate 
(SbV) considered as a pro-drug, which is further converted 
to trivalent antimonite (SbIII), an active form of the drug 
albeit to the parasite is also susceptible to SbV[16]. The 
reduction of pentavalent to trivalent compound takes place 
either in macrophages or in the parasite however, it is still a 
dilemma[17]. Parasite mediated reduction has been found to 
be associated with the loss of reductase activity of parasite, 
which may also lead to drug resistance. This is supported 
by the observation that SbV resistant Leishmania donovani 
amastigotes lose their reductase activity. The recent finding 
of a parasite thiol dependent reductases (TDR) 1 enzyme, 
that catalyze the conversion of SbV to SbIII using glutathione 
as a reductant also supports this possibility[18]. In addition, 
arsenate reductase 2 (ACR2) a new antimoniate reductase 
characterized in Leishmania sp. increases sensitivity of 
parasites to SbV[19]. It has also been reported that this 
reduction takes place primarily in macrophage rather 
than parasite[20]. The supporting evidences that come from 
organisms like bacteria and yeast, where the metal reduction 
is mediated by host specific enzymes suggests that this 
conversion is host specific[21]. 
  The routes of antimonials entrance into Leishmania 
and macrophages are not known. However, parasitic 
aquaglyceroporin, aquaporin 1 transporter is supposed 
to be responsible for the transport of antimonials into 
amastigotes[22]. In addition, the transport of SbV via 
phosphate transporters is based on the fact that pentavalent 
arsenate, a metal related to SbV, is able to enter the 
parasite[21]. Both form of antimonials SbV and SbIII, kills 
Leishmania species by DNA fragmentation, suggesting 
the role of apoptosis, 毬-oxidation of fatty acid and 
adenosine diphosphate phosphorylation. However, the 
exact mechanisms of action are still unexplored[23-25]. In 
addition, the antimonials inhibit glycolysis and metabolic 
pathways and increases efflux of intracellular thiols by a 
ATP binding cassette (ABC) transporter, multi drug resistant 
protein A (MRPA)[26]. Pentamonials are also known to 
inhibit trypanothion reductases, an enzyme responsible for 
protection from host reactive oxygen and nitrogen species to 
parasites[27]. 
  The widespread misuse of drug, as it was easily available 
over the counters in endemic regions; along with loss 
of drug activation by parasites are the major causes of 
acquired resistance. The in vitro studies on SbV resistant 
Leishmania axenic amastigotes and promastigotes indicate 
their diminished ability to reduce SbV to SbIII[10]. A study 
on amastigote and promastigote forms of SbIII resistant 
Leishmania, have shown reduction in accumulation of 
metals due to either reduced uptake or increased efflux[28]. 
Overexpression of a heat shock protein (HSP70) gene 
has been found to be associated with the antimonial 
resistance[29]. The transporters of ABC family, MRPA and 
pentamidine resistant protein 1(PRP1) that act as efflux pump 
for antimonials,are also linked to antimony resistance[15,30]. 
Further, various genes identified in antimonial unresponsive 
clinical isolates suggests the multifactorial mechanism of 
resistance[31-34]. 
2.2. Amphotericin B (AmB) 
  It is a polyene antifungal drug widely used to treat 
systemic fungal infections[35]. In endemic areas of Bihar 
where antimonials resistance is common, AmB is the 
drug of choice[36]. AmB shows high affinity for ergosterol, 
the predominant sterol of fungal and leishmanial cell 
membrane. Despite its high efficiency, AmB is also toxic 
and its side effect has been reported[37,38]. Adverse effects 
of plain AmB have been circumvented with its three clinical 
formulations in which deoxycholate have been replaced 
by other lipids. These formulations are liposomal AmB 
(L-AmB: Ambiosome), AmB colloidal dispersion (ABCD: 
Amphocil) and AmB lipid complex (ABL: Abelcit). These 
lipid formulations of AmB retain their antifungal activity 
and show very high efficacy to cure this deadly disease and 
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are less toxic. In VL cases, liposomal AmB has been proved 
as an efficient drug with more than 95% efficacy but high 
cost limits its use to common man suffering from this deadly 
disease. 
  The antileishmanial activity of AmB and its lipid 
formulation is due to its interaction of both sterols 
i.e. ergosterol of Leishmania and cholesterol of host 
macrophages. Since cholesterol is complexed by AmB, 
it markedly inhibits binding Leishmania donovani 
promastigotes to macrophage[39]. Further, at higher 
concentration (<0.1 M), it induces the formation of aqueous 
pores in leishmanial promastigotes cell membrane that 
result in osmotic changes leading to the cell lysis[40]. Inspite 
of excellent efficacy the administration of AmB is also 
associated with the toxicity and emergence of parasitic 
resistance. The damaging effect of AmB in kidney tubular 
cell is mainly due to increased salt and Ca2+ concentration, 
H+ permeability across the aqueous pores that lead to 
sustained collapse of pH and Ca2+ gradient across the 
membrane, a mechanism responsible for apoptosis in 
eukaryotic cells. The in vitro studies demonstrate that 
resistant Leishmania lacks ergosterol, the main target of 
AmB[41]. In Leishmania donovani AmB resistant strain, 
parasitic cell membrane lacks C-24 alkylated sterols 
that might be due to inactivation of enzyme S-adenosyl 
methionine transferase which is responsible for alkylation at 
C-24 position in ergosterol moieties leading to resistance[42]. 
Another study has shown that resistance to AmB was 
found to be associated with gene TarII 64.4 and tarII 512.2 
amplification in Leishmania tarentolae mutant cell lines[43]. 
Till date clinical resistance against AmB is not reported but 
the relative nonspecific mode of action of AmB at the level 
of membrane may be a factor for its infrequent resistance. 
It has been shown in a study that success of AmB treatment 
greatly depends on patient immunity status and indicate 
that successive relapse could enhance emergence of AmB 
resistant isolates[44,45]. These finding warrants the possibility 
of resistance against the most successful drug.
2.3. Miltefosine
  Miltefosine is originally developed as anticancerous agent, 
which is an alkylphosphocholine (hexadecylphosphocholine) 
moiety[46]. It is the first oral drug used for the treatment 
of VL and was considered a major breakthrough in anti-
leishmanial chemotherapy[47,48]. Its phase I/II/III trials 
provoked a storm of protection against VL that was followed 
by phase IV trial, which also proved its relevance in 
outpatient setting in those areas where VL is endemic[49,50]. 
The combination of miltefosine and ambisome has also 
been evaluated, and has been found effective with good 
tolerability but unfortunately side effects raise questions 
against extreme efficacy of this combinatio[51]. The main 
adherence of the drug is compromised by its long terminal 
residence, time and teratogenicity. Miltefosine has a median 
long half-life of approximately 152 hours, which could 
encourage development of clinical resistance. Further, 
its teratogenic and abortifacient nature limits its use in 
pregnancy. 
  The activity of miltefosine is due to intracellular 
accumulation of drug, which is regulated by two 
transporters, LdMT and its 毬-subunit LdRos3, a P-type 
ATPase, belonging to aminophospholipid translocase 
family[52]. In studies on resistant mutant of Leishmania, 
it is observed that due to decreased influx, accumulation 
of miltefosine inside the parasite is greatly hampered[52]. 
Although, the exact mode of antileishmanial action is still 
unclear but it has been found that it causes apoptosis like 
processes in Leishmania donovani as observed in amastigote 
but how it happens, still unknown[53]. Miltefosine also 
reduces the lipid content in promastigotes membrane and 
enhances the phosphatidylethanolamine content suggesting 
a partial inhibition of phosphatidylethanolamine-N-
methyltransferase that leads to decreased parasite 
proliferation[54]. 
  The clinical resistance is not yet reported but being an 
oral agent its improper use in endemic countries like 
India increases the probability of resistance and spread 
of resistance parasites where prevalence of infection is 
significantly high. This is now being observed that few 
patients after successful treatment with miltefosine relapsed 
after 9-12 months. However, more studies are required 
to understand whether these are relapse or reinfection or 
resistance. Broadly, decreased drug efflux is the main reason 
for miltefosine resistance in Leishmania, though many 
mechanisms are reported for this decreased intracellular 
drug concentration. It has been reported that single point 
mutation at LdMT and LDRos3 in experimental leishmaniasis 
may lead to resistance. In addition to LdMT, over expression 
of multidrug resistant MDR1 gene which encodes a 
glycoprotein is also responsible for drug resistance[55]. 
Furthermore, miltefosine resistance is also correlated with 
lipid content in parasite membrane. It has been observed 
that the amount of unsaturated phospholipid alkyl chains 
was lower in miltefosine resistance parasites[56].
2.4. Paromomycin
  Paromomycin is chemically an aminoglycosidic antibiotic 
and has both antileishmanial and antibacterial activity. 
Paromomycin cures both, VL and CL (more effectively) but 
limited availability restricts its use in endemic regions[57,58]. 
A controlled study on the efficacy of topical paromomycin 
sulfate and methylbenzethonium chloride in CL has 
shown total elimination of parasite within the first 10 days 
of treatment[59]. The Indian and Sudanese trials further 
demonstrate its high efficacy and excellent tolerability, 
which have also been comparable to AmB[60,61]. A phase II 
study in Tunisia and France has shown that WR279, 396, 
a formulation of paromomycin and gentamicin was found 
safe and highly effective  in treatment of CL. It offers great 
potential as a new, simple, easily applicable and expensive 
topical therapy for CL[62].
  The mechanism of paromomycin action is largely 
unclear. Its modus operandi in Candida krusei supports 
cytochrome C inhibition but in Leishmania requires further 
elucidation. Recently it has been shown that cationic 
paromomycin binds to the negatively charged leishmanial 
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glycocalyx suggesting mitochondria as a primary target[63]. 
In addition, paromomycin inhibits translocation and 
recycling of ribosomal subunits and hence protein 
synthesis. Paromomycin in Leishmania donovani promotes 
association of 50S and 30S subunits of both, cytoplasmic 
and mitochondrial ribosomes and stops their recycling 
that eventually inhibits protein synthesis[64]. Further 
exploration came from the study of Hirokoma et al that 
proves that paromomycin interacts with both 30S and 50S 
subunits without inhibiting the association of translation 
initiation factor-3 (IF3) to the 30S ribosomal subunit[65]. 
Due to its limited use resistance is not yet reported in 
outpatient treatment but resistance has been reported in 
vitro in Leishmania donovani and Leishmania tropica[63,66]. 
However, rapid emergence against paromomycin due to its 
aminoglycosidic nature cannot be over ruled. 
2.5. Sitamaquine
  Sitamaquine, chemically 8-aminoquinoline, is the only 
drug that was developed for treatment of VL. It was originally 
developed in collaboration with GlaxoSmithKline and 
Wlater Reed Army Institute[49]. The advantage of this drug 
is its oral administration. The phase II trial of sitamaquine 
in India demonstrated its efficacy against VL and was well 
tolerated[67]. However, despite efficacy few side effects like 
vomiting, dyspepsia, cyanosis, nephritic syndrome and 
glomerulonephritis were also observed. The consequences of 
Kenyan phase II trial were different from Indian trial[68]. The 
Kenyan trial showed somewhat equal efficacy but observed 
side effects were abdominal pain, headache and kidney 
dysfunctioning. 
  Sitamaquine at high concentration affects parasite motility, 
morphology and growth[69]. Mechanism of its action involves 
electrostatic interaction between phospholipid anionic polar 
head groups and positively charged sitamaquine and then 
with phospholipid acyl chains leading to drug insertion 
within biological membranes[70]. After binding to the 
membrane, sitamaquine accumulate in Leishmania cytosolic 
acidic compartments, acidocalcisome. However, correlation 
between its action and accumulation is not clear[71]. There is 
transient affinity between sitamaquine and membranes and 
also energy dependent efflux was demonstrated, suggesting 
the presence of an uncharacterized transporter[70]. Although, 
resistance against this drug has not been reported yet in 
clinical practices but, in vitro resistance against Leishmania 
donovani promastigote has been reported by selecting drug 
pressure of sitamaquine at 160 毺m concentration[72]. In 
one of the study, conducted on cutaneous leishmaniasis 
caused by Leishmania major on BALB/c mice, sitamaquine 
dihydrochloride did not reduce the parasite burden and 
lesion progression was continued. The lack of its efficacy 
and activity seriously restricted further clinical trials[73]. 
However, with available status of knowledge, more studies 
are required to understand its efficacy, mode of action as 
well as toxicity.
2.6.  Pentamidine 
  Pentamidine is an aromatic diamine used to cure 
leishmaniasis as a second line drug. Its isothionate and 
methansulphonate salts are mainly used for the treatment 
of VL. It was initially used to treat SbV refractory patients in 
India but its declining efficacy and high resistance risk has 
led to its closure in India. Some combinational strategies 
have also been tried with this drug. A study on antimony 
unresponsive patient revealed that combination of low 
dosage of pentamidine and allopurinol as compare to the 
full dosages of pentamidine are more effective and less toxic 
with and ultimate cure of 73% and 58%, respectively[74]. 
However, its efficacy is questionable in comparison to other 
drugs. A comparative study on pentamidine and meglumine 
antimoniate (glucantime) against CL due to Leishmania 
braziliensis in Peru shows that glucantime was more effective 
than pentamidine[75]. However, it has been found more 
effective to curb CL caused by Leishmania panamensis and 
Leishmania guyanensis[76,77]. 
  Although, its precise mode of action is not known, 
it is reported that the drug enters inside Leishmania 
donovani promastigote through arginine and polyamine 
transporters[78,79]. In a biochemical study it was found 
that in pentamidine resistant, Leishmania donovani 
and Leishmania amazonensis promastigote clones, drug 
resistivity is due to decreased uptake followed by increased 
efflux of drugs. There is alteration in polyamine carrier that 
might be responsible for the alteration in surface protein 
nature and content leading to decreased influx of drug. 
Furthermore, this drug gets accumulated in mitochondria 
and enhances efficacy of mitochondrial respiratory chain 
complex II inhibitors suggesting its leishmanicidal activities 
due to decreased mitochondrial membrane potential. It is 
also reported that it inhibit mitochondrial topoisomerase 
II[80]. Pentamidine is highly toxic; causes hypoglycemia, 
nephrotoxicity and hypotension etc. Pentamidine resistance 
mechanism is not well understood, but intracellular ABC 
protein PRP1 can confer resistance to pentamidine in 
intracellular stage of Leishmania[81]. 
  Despite the significant progress that has been made 
during last few years in chemotherapies for leishmaniasis, 
all drugs of this regimen have some limitations like price, 
feasibility, safety, efficacy, toxicity, side effects and 
probability of growing resistance. The most important 
consideration of present therapeutics is gradual increase in 
resistance to antimonials in particular and others in general, 
predominantly in Indian subcontinents. In recent years, 
clinical trials of combination therapies are operational[6]. 
Combination of two or more drugs could reduce treatment 
duration and drug doses and consequently drug toxicity 
but probabilities of resistance development against current 
available drug regimen cannot be denied. The main 
combination drugs currently under consideration are LAmB 
(Liposomal amphotericin B) and miltefosine, LAmB and 
paromomycin, LAmB and antimonials and paromomycin 
and antimonials in India and also being evaluated in other 
part of the world (www.clinicaltrials.gov). There is no 
vaccine candidate available, and current recent progress 
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on leishmanial research does not guaranty about future 
availability of candidate leishmanial antigens/immunogens. 
Hence, identification of novel drug targets and development 
of true antileishmanial agents should be the priority area of 
research. 
3. New potential drug targets
  Leishmaniasis is the only tropical disease, which is 
being treated by non-leishmanial drugs. Moreover, the 
exact mechanisms of action of these drugs are not clearly 
understood. The recent research funding from various 
organizations like WHO/TDR, Tropical Medicine Research 
Centre, USA and European Commission etc, to disease 
endemic countries like India and Sudan, only encourage 
clinical trials and diagnostic evaluation studies. Recent 
publications in leishmanial research reveals that focus 
is being made only on drug trials/combination therapy of 
available non-leishmanial drugs, evaluation of diagnostic 
and prognostic capability of available tools, and very little 
emphasis is being paid on other aspects by leishmanial 
biologist and researchers. In the past several decades very 
little emphasis has been made on novel control strategies in 
terms of new drug targets and vaccine candidates.  
  Search of new potential drug targets mainly focus on 
biochemical and metabolic pathways essential for parasite 
survival (Figure 1). The target enzymes of these pathways 
should have significant structural and functional difference 
from its mammalian counterparts for selective inhibition 
of target sites. Further, strategies to target more than one 
enzyme of a metabolic pathway simultaneously may prove 
more usefulness and effectiveness. 
Figure 1. An overveiw of potential drug targets in Leishmania species. 
The coloured boxes represent the potential drug targets. ODC: 
ornithin decarboxylase, SpdS: spermidine synthase, TR: trypanothion 
reductase, TDPX: trypanodoxin peroxidase, DHFR: dihydrofolate 
rudutase, DH: dihydrofolate, TH: tetrahydrofolate, DHFR-TS: 
dihydrofolate rudutase thymidylate-synthase, M-THF: methylene 
tetrahydrofolate, dTMP: deoxy thymidine monophosphate, dUMP: 
deoxy uridine mono phosphate, MAPKKK: mitogen activated proteins 
kinase kinase kinase. MAPKK: map kinase kinase, MAPK: map 
kinase, CDKs: cyclin dependent kinase, NT: nucleotide transporter, 
FT: folate transporter. MT: mitochondria, ER: endoplasmic reticulam.
 
3.1. Enzymes of polyamine biosynthesis
  The putrescine, spermidine and spermine, like polyamine 
play important role in growth and differentiation of parasite 
from promastigote to amastigote stage[82]. Polyamines not 
only involves in parasite growth and differentiation but also 
down regulates lipid peroxidation generated by oxidants 
compounds and makes the environment compatible for 
survival[83]. There is reduced polyamine metabolism 
during initial phase of parasite adaptation in varying 
environment from vector to host[84]. Parasites overexpress 
arginase, ornithine decarboxylase, s-adenosylmethionine 
decarboxylase (Adomet DC) and spermidine synthase, the 
enzymes involved in polyamine metabolism. However, 
polyamine pool remains unchanged or marginally affected 
during their growth and metabolism that imply existence 
of regulatory mechanisms[85]. Any of these regulatory 
mechanisms offer a greater possibility for a future drug 
target.  
  In Leishmania, arginine is converted to L-ornithine 
by enzyme arginase. L-ornithine is further converted to 
putrescine through decarboxylation by enzyme ornithine 
decarboxylase, which in turn converted to spermidine and 
spermine, the substances responsible for cell growth and 
proliferation of Leishmania as well as Th2 type response 
that is responsible for pathogen survival in mammalian 
host[86]. Being first step of polyamine metabolism, targeting 
arginase pathway will be highly beneficial. Inhibitors of 
polyamine biosynthetic pathway have shown antileishmanial 
activity. Adomet DC inhibitor cures animal leishmaniasis 
but have not been tested on humans and seeks further 
experimental studies[87]. However, failure of alpha-
difluoromethylornithine, a polyamine inhibitor used to 
treat trypanosomiasis, to cure leishmaniasis proves some 
differences between two closely related parasites. Therefore, 
more efforts are needed to discover Leishmania specific 
polyamine inhibitors[88]. The polyamine transporters 
(LmPOT1) that transport both putrescine and spermidine are 
also good targets that regulate the intracellular polyamine 
level. Hence, development of inhibitors to stop polyamine 
biosynthesis and transportation may be quite useful as novel 
antileishmanial therapies.
3.2. Peptidases
  Peptidases are increasingly being seen as potential drug 
targets[89]. Therapeutically, peptidase inhibitors have 
been successfully introduced to treat HIV, hypertension, 
pancreatitis and multiple myeloma. A total of 154 peptidases 
were found to be present in the Leishmania major genome, 
with example of serine, cysteine, aspartic, threonine and 
metallopeptidases. Two aspartic peptidases were found 
in the Leishmania major genome sequence, one with 
sequence similarity to presenlin1 (PS1), which is a multipass 
membrane peptidase and the other with intramembrane 
signal peptide peptidase (SPP)[90]. PS1 is potentially involved 
in autophagy while SPP cleaves the transmembrane domain 
Nisha Singh et al./Asian Pacific Journal of Tropical Medicine (2012)485-497490
of signal peptidase that may be vital drug target[91].
  Twenty-one threonine peptidases have been found in 
the Leishmania major genome, though all are classified as 
proteasome subunit[91]. The proteasome is a multisubunit, 
multicatalytic peptidase responsible for degradation 
of ubiquitinated proteins in the cytosol[92]. Similar to 
plasmodial and trypanosomatids proteasome, the proteasome 
of Leishmania is a potential therapeutic target, as the use of 
specific inhibitors has shown the proteasome to be necessary 
for growth of Leishmania maxicana promastigotes and 
amastigotes in vitro[93].
  The cysteine peptidase of the papain family are 
extensively studied peptidase of Leishmania, comprising 
the cathepsin-L like peptidases CPA and CPB, and the 
cathepsin-B like peptidase CPC, which are lysosomal. 
Neither CPA nor CPC are essential for survival of Leishmania 
maxicana in the host but, CPB has been found to be a 
virulence factor and may be targeted in initial phase of 
disease[94]. In addition, the use of an inhibitor specific to 
cathepsin-L like cysteine peptidase, K11777, has shown that 
these peptidases are necessary for the growth of parasites 
that indicates potential of the peptidase as a drug target[95].
  Among several serine peptidases of protozoan, subtilisin-
like serine peptidase, a part of the secretary endosomal 
system, which participate in processing of secreted 
proteins may be very useful as drug target. It has been 
shown that the subtilisin- like peptidases of Plasmodium 
are potential drug targets[96]. Investigation of the effect of 
serine peptidase inhibitors on the survival of Leishmania 
has shown that TPCK(N-tosyl-l-lysyl-chloromethylketone) 
and benzamidine both reduces viability and induce 
morphological changes in the Leishmania amazonensis 
promastigotes, suggesting serine peptidases could be useful 
potential drug targets[97]. 
3.3. Enzymes of glycosomal machinery 
  
  Leishmania like other trypanosomatids depends solely 
on their host for carbon source to fulfill its energy 
requirements. The amastigotes uptake blood glucose from 
mammalian blood stream and other essential component 
like fatty acids, amino acids receives from phagolysosome of 
macrophages. In trypanosomatids glycosomes, peroxisome 
like organelle, are found. These glycosomes plays important 
role in many metabolic activities like glycolysis, oxidation 
of fatty acid, lipid biosynthesis, and purine salvage 
pathways etc. Due to the result of these metabolic activities 
superoxide radicals are generated as side products in large 
amount. To protect glycosomal enzymes from superoxide 
radical toxicity Fe-superoxide dismutase (FeSOD's ) are 
evolved in Leishmania species. In Leishmania chagasi two 
different types of FeSOD, Lcfesodb1 and Lcfesodb2 have 
been characterized, which are differentially expressed in 
stationary promastigotes, amastigotes and early logarithmic 
promastigotes stage, respectively. These are responsible 
for survival and protection from lethal superoxide radicals 
within glycosomes[98]. More importantly, FeSod is absent 
in mammalian counterpart, so it could be used as effective 
drug target. 
  Moreover, inside glycosome first seven steps of 
glycolysis occur whereas rest three occurs in cytosol. 
Enzymes hexokinase (HKK), phosphofructokinases (PFK) 
are autocatalytic enzymes and their hexose phosphate 
intermediates accumulation are lethal for parasite, thus 
in trypanosome unique mechanism has been evolved to 
escape this lethality. The first seven steps of glycolysis have 
no net gain of ATP and rest steps occur in cytosol and that 
result in ATP production. This unique compartmentalization 
regulates HXK and PFK autocatalysis, which depend on 
ATP[99]. These glycolytic enzymes are essential for parasite 
survival and enzymes of glycosomes may be targeted due to 
presence of unique targeting signal sequences, PTS1& PTS2 
present either on N-terminal or C-terminal end of these 
enzyme. If the targeting sequences are disrupted may lead 
to mistargeting and degradation of essential enzymes of 
glycolysis that creates lethality[100]. Thus unique organization 
of glycolytic pathway and evolutionary distance from 
mammalian host posing leishmanial glycolytic intermediate 
enzymes could be potential drug targets, however due to 
conserved glycolytic machinery single enzymatic inhibition 
will not be sufficient to marshal with parasite survival or 
death.
 
3.4. Enzymes of thiol metabolic 
  The Leishmania parasite survives and proliferates in 
hazardous environment of macrophage in mammalian 
host. This remains a puzzle that how parasite escape 
from reactive oxygen and reactive nitrogen species that is 
generated by host as immune effectors mechanisms against 
parasite. Recent reports indicate that parasite has developed 
unique defense mechanism to marshal respiratory burst 
activities of macrophages. Cascades of three antioxidant 
enzyme of trypanothion metabolism are required to 
counteract mammalian antioxidant glutathione metabolism. 
Trypanosomatids contain trypanothion [T(SH)2], a dithiol 
instead of a  glutathione as a main reductant and replaced 
the ubiquitous GSH/glutathione reductase redox couple with 
its T(SH)2 /trypanothion reductase(TR) system[101,102]. Why 
T(SH)2 is evolved inside parasitic system remain an enigma.
  TR is a flavoenzyme that reduces thioredoxin and 
tryparedoxin and some short chain protein like dithiol. 
These reactions delivers reducing equivalent to peroxidase 
for detoxification of toxic radicals produced during 
hydroperoxide and deoxyribonucleotide synthesis. 
Trypanothion enable metabolic pathways by maintaining low 
molecular mass thiols trypanothione and monoglutathionyl 
spermidine, glutathiol and ovathiol in their reduced state 
i.e. important for the uninterrupted progression of metabolic 
pathways[103].
  In Trypanosoma brucie and Leishmania infantum it is 
reported that T(SH)2  is capable of reducing NO and Fe into 
a harmless stable dinitrosyl iron complex with 600 time 
more affinity than mammalian GSH reductase system, that 
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protects parasites from potentially lethal nitric oxide (NO) 
molecule. The absence of this pathway in mammalian host 
and trypansomatids sensitivity towards oxidative stress, 
trypanothione reductase and enzymes of trypanothione 
metabolism are an attractive drug targets for antileishmanial 
drug designing[104]. Homology modeling of Leishmania 
infantum, TR and mammalian glutathione reductase show 
remarkable difference in their three dimensional and 
catalytic active sites. Hence specific inhibitors designed 
against TR may be an ideal drug that will stop parasite 
growth without altering host glutathion reductase (GR) 
activity.
3.5. Cyclin dependent kinases
  Cyclin dependent kinases (cdks) play crucial role in cell 
division cycle, transcription, apoptosis and differentiation. 
The genomic analysis has reported 10 orthologous cyclin 
in Leishmania species. In Leishmania major one additional 
mitotic like cyclin, CYCA is also found[105,106]. Cdk requires 
active cyclin for its own activation while few cdks requires 
activation by the phosphorylation for their functional 
activity. This phosphorylation could be achieved by cdc2 
activating kinases, at their conserved threonine residues 
(t-loop)[107]. Cdk related kinase3 (CRK3 gene) encodes cdc2 
related protein kinase with activity matching to eukaryotic 
histone H1. CRK3 is active at G2/M phase of Leishmania cell 
cycle. In Leishmania mexicana, disruption of CRK3 leads to 
change in cell ploidy though it was avoided when extra copy 
of CRK3 was expressed from episome ensuring that CRK3 is 
essential[108]. The chemical inhibitors of CRK3 impair the 
parasite viability within macrophage, thus validating CRK3 
as potential drug target. The most potent inhibitor of CRK3 
belongs to indirubin class, which provides pharmacophores 
for further drug development[105]. In Leishmania donovani, it 
was recently shown that glycogen synthase kinase (LdGSK3) 
is also involved in cell cycle control and apoptosis based on 
indirubin test[109] exploiting the LdGSK3 as potential drug 
target in combination with CRK3. Likewise, other cdk may 
also be explored as possible targets.
 
3.6. Mitogen activates proteins kinases  (MAPK)
  In mammals MAPK play important role in all aspects of 
immune response from initiation of innate immunity to 
activation of adaptive immunity. In addition, they also 
regulate cell differentiation, proliferation and apoptosis. 
MAPK receiver molecules, receive external stimuli and 
signals, and through cascades of intermediates regulate 
transcriptional, proliferative and differentiation status 
of a cell[110]. In Leishmania mexicana, 15 MAPK have 
been identified[110,111]. Leishmania mutant lacking MAPK 
gene has shown their significance in transformation and 
cellular growth. The MAPK gene deleted promastigotes 
after differentiation into amastigote lose proliferative 
capacity, also peritoneal macrophages were able to cope 
with infection, which their importance for amastigotes[112]. 
MAPKs are not only important to amastigotes but also 
for promastigotes. The direct evidence came from the in 
vitro study on overexpression of Leishmania major MAPK 
shows stage specific phosphotransferase activity and 
accumulation in axenic amastigotes not in promastigotes[113]. 
Identification of Leishmania specific sequences of MAPK 
and their targeting offers great probability for an effective 
drug. Leishmania MAPK inhibitors should have same effect 
on amastigote survival as in case of gene deletion. Hence 
efforts are required to identify leishmanial MAPK related 
targets. These kinases may be potential drug target not 
only for the development of novel drug regimen but also for 
therapeutic immunomodulation.
3.7. Enzymes of sterol biosynthesis
 
  In Leishmania species the main endogenous sterols are 
ergosterol and stigmasterol, which differs from mammalian 
counterpart cholesterol, therefore can be used as potent 
drug targets. Ergosterol has two important functions: first, 
it is a structural component of cell membrane and second, 
it might play hormonal role. AmB sounds strongly against 
leishmaniasis because of sterol based mechanism of action, 
but AmB resistance for leishmaniasis dictates researchers 
to find an alternative drug of AmB deliberately. Azasterols, 
a known class of s-adenosyl-L-methionine, show 
antileishmanial activity and inhibits 24-methyltransferase, 
which is a vital enzyme in ergosterol biosynthesis[114]. 
Other sterols like azol and triazole are also effective 
against Leishmania, which inhibits 14毩-methylsterol 14-
demethylase. However, Leishmania has potential to survive 
in altered sterol profile, and also have ability to utilize 
and metabolize host sterol[85]. This consideration must 
be accounted during novel drug development. The most 
appropriate way will be the inhibitors of sterol biosynthesis 
with other metabolic pathway combined together. Along with 
the combinational therapy, to find some another potential 
sites in sterol biosynthetic pathway that can be used as 
attractive drug targets.
3.8. Dihydrofolate reductase (DHFR)
  DHFR is a key enzyme in folate metabolism, linked to the 
production of thymidine[115,116]. DHFR reduces dihydrofolate 
to tetrahydrofolate using NADPH as cofactor. Therefore, 
inhibition of DHFR prevents biosynthesis of thymidine 
and as a consequence, DNA biosynthesis. Fortunately, this 
enzyme from Leishmania major and Trypanosoma cruzi have 
been crystallized and the structural data may be exploited 
to observe structural difference between parasite and 
human enzymes that may help to design selective DHFR 
inhibitors[117,118]. An approach to discover novel parasite 
DHFR inhibitors using database mining has also been made 
to search the Cambridge structural database but DHFR as 
drug target requires further attention[119,120]. In addition, 
enzyme dihydrofolate reductase-thymidylate (DHFR-TS) 
that catalyzes conversion of dihydrofolate from methyhylene 
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tetrahydrofolate(M-THF) and thymidine, has been shown 
to be related to parasite survival and parasite lacking this 
enzyme are not able to survive in animals[121]. Inspite of 
these advantages several potential resistance mechanisms 
to DHFR have been discovered including over-expression of 
the enzyme DHFR-TS and enzyme ptrI[122,123]. The enzyme 
ptr1 predominantly involved in reduction of biopterin to 
dihydrobiopterin and tetrahydrobiopterin but also capable 
of reducing dihydrofolate to tetrahydrofolate. Hence, a 
combined strategy to target both DHFR and ptrI in will be 
more effective as a true antileishmanial drug.
3.9. Topoisomerases 
  DNA topoisomerases are ubiquitous enzymes needed to 
remove torsional stress in DNA by introducing transient 
protein-bridge DNA breaks either on one (type I) or 
both (type II) DNA strands. Topoisomerases are major 
targets in cancer and bacterial chemotherapy[124,125]. In 
parallel protozoan parasites are not distinct, they require 
topoisomerase specially topoisomerase II due to the 
presence of complex intercatenated network of thousands 
of minicircles as well as maxicircles in kinetoplastids 
mitochondria. Topoisomerase II has been reported to be 
overexpressed and shows increased activity in arsenite 
resistance Leishmania donovani[126]. The topological 
problem associated with mitochondrial DNA presents 
potential sites for topoisomerase II activity. Antibacterial 
and anticancerous drugs like novobiocin, etoposide, and 
fluoroquinolones can be used to target topoisomerase II in 
order to inactivation of genetic integrity and cell survival[127]. 
More efforts are required towards topoisomerase targeted 
drug interaction and development of anti-topoisomerase 
chemicals against drug resistant Leishmania parasites.
3.10. Metacaspases 
  Metacaspases are orthologous to caspases that play 
crucial role in apoptosis but imperfectly understood in 
protozoa. It has been found that metacaspases may be 
possible candidates to induce programmed cell death 
in trypasomatids[128]. In Leishmania donovani two 
metacaspases: LdMCA1 and LdMCA2 are reported showing 
98% homology with each other and contain characteristic 
C terminal proline rich domain and both are expressed in 
promastigotes and amastigotes form[129]. A metacaspase from 
Leishmania major (LmjMCA) has found to be essential for 
the proper segregation of the nucleus and kinetoplast[130]. 
Metacaspase gene of Leishmania major is actively expressed 
in amastigotes and procyclic promastigotes but surprisingly 
at a lower level in metacyclic promastigotes. Metacaspases 
in Leishmania, on treatment with H2O2 trigger process of 
programmed cell death of parasites. It has also been found 
that parasites, which over express metacaspases are more 
sensitive to H2O2 induced programmed cell death[131]. 
Molecules that can target to metacaspase biosynthetic 
machinery and induces their early expression might prove as 
efficient antileishmanial agents. In addition, since they are 
required for chromosomal segregation and parasite survival, 
they can also be directly targeted[132]. However, more 
studies are required to understand the complete function of 
leishmanial metacaspases.
3.11. Leishmanial antigens that modulates host immune 
functions
  Lei shmania  surv iva l  and pro l i fe ra t ion  wi th in 
parasitophorous vacuole primarily depends on its strategy 
to evade macrophage effector molecules and diverting its 
immune response. Macrophage arsenal is full of its potent 
armatures such as reactive nitrogen and oxygen species, 
lysozymes, and other microbicidal molecule, production 
of variousTh1 cytokines for parasitic inhibition[133]. On 
parasitic infection the chase begin, macrophage attack on 
parasite with its reactive nitrogen and oxygen molecules 
as a result of induction of respiratory burst activity, while 
parasite has to defend itself for its survival, it has to 
produce something that will counterattack and suppress 
this activity or develop a strategy to skip from this attack. 
Leishmania survival strategy includes: (1) its glycoprotein 
(gp63: a metalloproteinase) facilitates binding of metacyclic 
promastigotes to macrophages via CR3 receptor without 
eliciting oxidative burst in macrophages, (2) It inactivates 
complement components C3, C5, C9 by phosphorylation, 
(3) The parasitic superoxide dismutase scavenges reactive 
oxygen intermediates, (4) It suppresses iNOS expression of 
host macrophages, and (5) It induces disease exacerbating 
Th2 cytokines production such as TGF-毬 and IL-10 and 
suppresses the production of Th1 cytokines viz. IL-4, IL-
12 etc[134]. Further, Leishmania parasite also alters various 
signaling cascades by induction of PTPase activity of 
host leading to down regulation or inactivation of various 
signaling cascade intermediates like NF-毷毬, AP1, STAT1 
etc that ultimately lead to the down regulation RNI, ROS, 
Nramp1 and other immune responses of macrophage[135].
  One of the other survival strategies is the down regulation 
or dysfunctioning of ion transporters recruited on the 
cell membrane of phagolysosomes. The divalent cationic 
transporters creates Fe2+, Mn2+, Zn2+ deprived environment 
inside the phagosomes by pumping them out. These ions 
specifically iron is required for various crucial processes 
like antioxidant defense (Fe-Sod), mitochondrial respiration 
and DNA replication that are required for parasitic growth 
and survival[136]. The Leishmania parasite effectively down 
regulates or blocks the activity of these transporters but the 
mechanisms are not known. However, a divalent cations 
transporter natural resistance associated with macrophage 
protein1 (NRAMP1) now referred as SLC11A1 that belongs to 
a divalent cations transporter solute carrier family, play an 
important role in host resistance against diverse pathogenic 
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organism such as Salmonella, Mycobacterium and 
Leishmania by maintaining cations deficient environment 
inside the phagolysomes[137]. NRAMP1 is exclusively 
expressed on professional phagocytes and pumps out cations, 
required for parasitic growth and survival, from phagosomal 
milieu to cytosolic compartment of macrophage (Figure 
2). The parasite expresses Leishmania iron transporter ZIP 
family one (LIT1) transporter, which transport Fe2+ inside 
parasite[138]. It seems that some parasitic proteins, soluble, 
surface or excretory-secretory, modulate Nramp1 pump 
function during leishmanial pathogenesis. These leishmanial 
antigens might work as potential drug targets but they are 
needed to be identified and characterized for development 
of drug and vaccine candidates.
Figure 2. The figure summarizes the role of NRAMP1 in pathogenesis 
of leishmaniasis. Some leishmanial antigens may also upregulate 
PTPase functional activity, which further downregulate (inhibit 
phosphorylation) AP1, STAT1, IRF1 etc like transcription factors. 
Without phosphorylation they are not activated and bind to the 
promoter of NRAMP1, iNOS, SOD genes etc in macrophage and 
reduce their expression.
4. Conclusion and perspectives
  Leishmaniansis is a life threatening disease that affects 
predominantly to people of developing countries living below 
poverty line. In disease endemic regions poor sensitizations, 
malnutrition and unhealthy living environment factors are 
the main reason for its pathogenesis and manifestations. The 
migration of population from endemic to nonendemic areas, 
and tourist activities in endemic regions are primary cause 
of disease spread in newer areas. To control the spread of 
disease in endemic countries, effective control measures for 
both, the vector and parasites are still required. The growing 
incidences of resistance with available drug regimen 
warrants the precise use antileishmanial drugs as well as 
necessitates the development of newer cost effective drugs 
and vaccine candidates. During past couple of decades 
the leishmanial research has made significant progress 
in various research areas but unfortunately identification 
of novel drug targets and drugs is far from satisfactory. 
In addition, the unavailability of either prophylactic or 
preventive vaccine candidates further makes difficult the 
control of disease. It has now become essential to identify 
priority research areas to combat disease progression 
worldwide.
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